Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial (Q28278620)

10

object named as

Howard L Weiner

0 references

Ivana Kovářová

0 references

author name string

Alasdair J Coles

1

0 references

Cary L Twyman

2

0 references

Douglas L Arnold

3

0 references

Jeffrey A Cohen

4

0 references

Christian Confavreux

5

0 references

Edward J Fox

6

0 references

Eva Havrdova

8

0 references

Krzysztof W Selmaj

9

0 references

Tamara Miller

11

0 references

Elizabeth Fisher

12

0 references

Rupert Sandbrink

13

0 references

Stephen L Lake

14

0 references

David H Margolin

15

0 references

Pedro Oyuela

16

0 references

Michael A Panzara

17

0 references

D Alastair S Compston

Defining interferon beta response status in multiple sclerosis patients.

18

0 references

language of work or name

English

0 references

publication date

24 November 2012

0 references

published in

The Lancet

0 references

volume

380

0 references

issue

9856

0 references

page(s)

1829-39

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Some large-sample distribution-free estimators and tests for multivariate partially incomplete data from two populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Two-Sample Asymptotically Distribution-Free Tests for Incomplete Multivariate Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2961768-1

7 January 2021

10.1016/S0140-6736(12)61768-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23122650

1 reference

Consolidated OpenCitations Corpus – April 2017